Nuvalent, Inc. Class A (NUVL)
NASDAQ:NUVL
Want to see NUVL full AI Analyst Report?
NUVL Stock Chart & Stats
$107.61
-$0.36(-0.45%)
At close: 4:00 PM EST
$107.61
-$0.36(-0.45%)
Day’s Range― - ―
52-Week Range$71.13 - $113.02
Previous CloseN/A
Volume65.93K
Average Volume (3M)716.84K
Market Cap
$7.12B
Enterprise Value$7.96B
Total Cash (Recent Filing)$1.29B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 06, 2026EPS Estimate
-1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.06
Shares Outstanding73,562,660
10 Day Avg. Volume1,043,553
30 Day Avg. Volume716,842
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)5.86
Price to Sales (P/S)0.00
P/FCF Ratio-26.57
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.95
Forecast
1Y Price Target
$141.60Price Target Upside31.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-5.7
Revenue Forecast (FY)$11.67M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA debt-free balance sheet with sizable equity provides durable financial flexibility to fund multi-year clinical programs and regulatory review periods. This reduces refinancing urgency, supports continued R&D investment, and improves viability through the typical clinical-to-commercial inflection timeline.
Regulatory Milestone (NDA)Submission of an NDA for neladalkib is a structural advancement: it transitions the program from development to regulatory review, materially raising the probability of commercialization or partnership. Progress through FDA review can unlock licensing, milestones, and future revenue streams if approved.
Focused, Differentiated PipelineA concentrated pipeline targeting genetically defined cancers and resistance/CNS limitations addresses high unmet medical needs. Such precision oncology focus can yield durable competitive advantages and premium commercial dynamics if clinical efficacy and safety are demonstrated.
Bears Say
Pre-revenue With Widening LossesBeing pre-revenue while net losses have expanded materially increases dependence on external capital. Without product sales, the company must bridge clinical development to approval, leaving long-term profitability and shareholder returns uncertain until commercialization occurs.
Accelerating Cash BurnRapidly increasing cash consumption pressures runway and forces periodic financing. Persistent negative operating and free cash flow undermines resilience to trial setbacks and can lead to dilution or constrained program spending if capital markets tighten over the next several quarters.
Reliance On Financing (no Commercial Revenue)With no recurring product sales, the business model depends on equity or other financings to fund R&D and trials. This structural reliance exposes the company to market funding cycles, potential dilution, and execution risk if future financing terms are unfavorable or unavailable.
Nuvalent News
NUVL FAQ
What was Nuvalent, Inc. Class A’s price range in the past 12 months?
Nuvalent, Inc. Class A lowest stock price was $71.13 and its highest was $113.02 in the past 12 months.
What is Nuvalent, Inc. Class A’s market cap?
Nuvalent, Inc. Class A’s market cap is $7.12B.
When is Nuvalent, Inc. Class A’s upcoming earnings report date?
Nuvalent, Inc. Class A’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.
How were Nuvalent, Inc. Class A’s earnings last quarter?
Nuvalent, Inc. Class A released its earnings results on May 07, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.34 by -$0.05.
Is Nuvalent, Inc. Class A overvalued?
According to Wall Street analysts Nuvalent, Inc. Class A’s price is currently Undervalued.
Does Nuvalent, Inc. Class A pay dividends?
Nuvalent, Inc. Class A does not currently pay dividends.
What is Nuvalent, Inc. Class A’s EPS estimate?
Nuvalent, Inc. Class A’s EPS estimate is -1.41.
How many shares outstanding does Nuvalent, Inc. Class A have?
Nuvalent, Inc. Class A has 73,562,660 shares outstanding.
What happened to Nuvalent, Inc. Class A’s price movement after its last earnings report?
Nuvalent, Inc. Class A reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.34. Following the earnings report the stock price went down -1.784%.
Which hedge fund is a major shareholder of Nuvalent, Inc. Class A?
Currently, no hedge funds are holding shares in NUVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvalent Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$141.60 (31.59% Upside)
$141.60 (31.59% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 310.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 14.2%
Last 30 Days ▲ 19.1%
Last 30 Days ▲ 19.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.39%
12-Months-Change
Fundamentals
Return on Equity
-42.78%
Trailing 12-Months
Asset Growth
20.38%
Trailing 12-Months
Company Description
Nuvalent, Inc. Class A
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL Stock 12 Month Forecast
Average Price Target
$141.60
▲(31.59% Upside)
Technical Analysis
Ownership Overview
26.63% Insiders
30.84% Mutual Funds
2.96% Other Institutional Investors
27.10% Public Companies and
Individual Investors